This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Telmisartan Versus Ramipril After Acute Coronary Syndrome (TERACS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Catholic University of the Sacred Heart.
Recruitment status was:  Recruiting
Information provided by:
Catholic University of the Sacred Heart Identifier:
First received: June 19, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome

Condition Intervention Phase
Acute Coronary Syndrome Myocardial Infarction Coronary Disease Drug: TELMISARTAN Drug: RAMIPRIL Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome

Resource links provided by NLM:

Further study details as provided by Catholic University of the Sacred Heart:

Primary Outcome Measures:
  • High sensitivity C-Reactive Protein [ Time Frame: 20 days after hospital discharge ]

Secondary Outcome Measures:
  • Endothelial Progenitor Cells [ Time Frame: 20 days after hospital discharge ]

Estimated Enrollment: 50
Study Start Date: November 2007
Estimated Study Completion Date: November 2008
Estimated Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: R
Twenty-five patients assigned to ramipril 5 mg daily
5 mg daily
Active Comparator: T
Twenty-five patients assigned to Telmisartan 80 mg daily
80 mg daily


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
  • presence of ECG ischemic changes,
  • angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography,
  • successful coronary revascularization of at least one culprit coronary vessel.

Exclusion Criteria:

  • Age>80 years, current ACE inhibitor or ARB treatment,
  • ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand,
  • ECG abnormalities that could affect the recognition of ST segment shift,
  • recent or chronic infective or inflammatory diseases,
  • malignancy, and myocardial infarction,
  • surgery or trauma in the previous month.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00702936

Contact: Italo Porto, MD, PhD 0039(0)6-30154127
Contact: Italo Porto, MD, PhD

Catholic University of the Sacred Heart Recruiting
Rome, Italy, 00168
Contact: Italo Porto, MD, PhD   
Contact: Luca Di Vito, MD   
Principal Investigator: Italo Porto, MD, PhD         
Sub-Investigator: Luca Di Vito, MD         
Sponsors and Collaborators
Catholic University of the Sacred Heart
Principal Investigator: Italo Porto, MD, PhD Catholic University of the Sacred Heart
Principal Investigator: Luca Di Vito, MD Catholic University of the Sacred Heart
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Catholic University of the Sacred Heart Identifier: NCT00702936     History of Changes
Other Study ID Numbers: ILG-1
Study First Received: June 19, 2008
Last Updated: June 19, 2008

Additional relevant MeSH terms:
Myocardial Infarction
Acute Coronary Syndrome
Coronary Disease
Coronary Artery Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors processed this record on July 26, 2017